Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Sep 30, 2025	Dec 31, 2024
Cash & Equivalents	91.25	61.58
Short-Term Investments	257.9	314.07
Cash & Short-Term Investments	349.16	375.65
Prepaid Expenses	6.01	1.22
Total Current Assets	355.16	376.87
Property, Plant & Equipment	2.22	1.04
Long-Term Investments	151.76	18.07
Other Long-Term Assets	0.1	0.04
Total Assets	509.25	396.02
Accounts Payable	2.21	3.46
Accrued Expenses	8.66	9.37
Current Portion of Leases	0.42	0.21
Total Current Liabilities	20.97	13.04
Long-Term Leases	1.49	0.76
Total Liabilities	22.46	13.8
Common Stock	0.05	0.04
Additional Paid-In Capital	643.2	463.02
Retained Earnings	-159.57	-83.72
Comprehensive Income & Other	0.19	-0.04
Total Common Equity	483.86	379.29
Shareholders' Equity	486.79	382.22
Total Liabilities & Equity	509.25	396.02
Total Debt	1.91	0.97
Net Cash (Debt)	499.01	392.75
Net Cash Per Share	11.62	23.39
Filing Date Shares Outstanding	48.41	37.44
Total Common Shares Outstanding	48.38	37.44
Working Capital	334.2	363.83
Book Value Per Share	10.00	10.13
Tangible Book Value	483.86	379.29
Tangible Book Value Per Share	10.00	10.13

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q